** Shares of Orthocell OCC.AX rise 15.4% to A$1.500, their highest levels since Jan 6
** The regenerative medicine firm says that it plans to enter key markets such as Canada and Thailand, among others, in CY2025
** Orthocell recently submitted its USFDA regulatory application for the clearance to distribute its nerve drug Remplir in the $1.6 bln (A$2.55 bln) U.S. market commercially
** Co expects approval in March/April 2025
** About 3.4 mln shares trade hands, 1.9 times the 30-day average of 1.8 mln
** Stock rose 230.5% in 2024
(1 Australian dollar = $0.6266)
(Reporting by Manasi Dasa Sundeep in Bengaluru)
((Manasi.DasaSundeep@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。